Company / Depreciation & Amortization
BioMarin Pharmaceutical Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$79.6M
FY2025
5-year range
$79.6M / $108.0M
FY2021-FY2025
Trend
-17.5%
vs FY2024
Sector context
#25 of 168
Health Care
What the data says
BioMarin Pharmaceutical's depreciation & amortization of $80M is higher than 85% of companies in the Health Care sector (FY2025). Depreciation & Amortization has fluctuated over the past 10 years, ranging from $80M in FY2025 to $108M in FY2021.
Based on SEC 10-K filings.
$80M in FY2025 with a 5-year CAGR of -5.4%. Top quartile in the Health Care sector.
Improved from $104M to $80M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -7.9%
- 5-Year CAGR
- -5.4%
- 10-Year CAGR
- -
Sector benchmark
-62.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.4%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 17.5% year-over-year.
- Ranks #25 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $79.6M | -17.5% |
| FY2024 | $96.4M | -7.6% |
| FY2023 | $104.4M | +2.4% |
| FY2022 | $102.0M | -5.6% |
| FY2021 | $108.0M | +2.7% |
| FY2020 | $105.2M | -0.1% |
| FY2019 | $105.3M | +10.1% |
| FY2018 | $95.7M | +8.9% |
| FY2017 | $87.9M | -9.3% |
| FY2016 | $96.9M | +105.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026